Population-based screening for Lynch syndrome in Western Australia

International Journal of Cancer

Volumn 135, Issue 5, 2014, Pages 1085-1091

  Schofield, Lyn ^a,b   Grieu, Fabienne ^c   Amanuel, Benhur ^a,c   Carrello, Amerigo ^c   Spagnolo, Dominic ^a,c   Kiraly, Cathy ^b   Pachter, Nicholas ^a,b   Goldblatt, Jack ^a,b   Platell, Cameron ^a,d   Levitt, Michael ^d   Stewart, Colin ^b   Salama, Paul ^a,e   Ee, Hooi ^c   Raftopoulous, Spiro ^c   Katris, Paul ^f   Threlfall, Tim ^g   Edkins, Edward ^h   Wallace, Marina ^a   Iacopetta, Barry ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Department of Anaesthesia and Pain Medicine   (United States)

^c SIR CHARLES GAIRDNER HOSPITAL   (United States)

^d St John of God Subiaco Hospital   (United States)

^e ROYAL PERTH HOSPITAL   (Australia)

^f Cancer Council WA   (United States)

^g Health Department West Australian Cancer Registry   (United States)

^h Diagnostic Genomics PathWest Laboratory Medicine QEII Medical Centre   (United States)

Author keywords

colorectal cancer; Lynch syndrome; microsatellite instability; screening

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; BRAF GENE; CANCER SCREENING; COHORT ANALYSIS; GENETIC SCREENING; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MLH1 GENE; MUTATIONAL ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL;

COLORECTAL CANCER; LYNCH SYNDROME; MICROSATELLITE INSTABILITY; SCREENING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; GENETIC TESTING; HUMANS; MASS SCREENING; MICROSATELLITE INSTABILITY; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; WESTERN AUSTRALIA;

EID: 84902532682     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28744     Document Type: Article

References (31)

1. Lynch HT, de la Chapelle A,. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-32.
2. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-60.
3. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41: 664-8.
4. Parsons MT, Buchanan DD, Thompson B, et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: A literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012; 49: 151-7.
5. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26: 5783-88.
6. Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012; 308: 1555-65.
7. Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001; 121: 830-8.
8. Piñol V, Castells A, Andreu M, et al. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite |instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293: 1986-94.
9. Schofield L, Watson N, Grieu F, et al. Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 2009; 124: 1097-1102.
10. Ward RL, Hicks S, Hawkins NJ,. Population-based molecular screening for Lynch syndrome: Implications for personalized medicine. J Clin Oncol 2013; 31: 2554-62.
11. Stoffel EM, Chittenden A,. Genetic testing for hereditary colorectal cancer: Challenges in identifying, counselling, and managing high-risk patients. Gastroenterology 2010; 139: 1436-41.
12. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-56.
13. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-8.
14. van Dijk DA, Oostindiër MJ, Kloosterman-Boele WM, et al. Hereditary Tumor Study Group of the Comprehensive Cancer Centre West. Family history is neglected in the work-up of patients with colorectal cancer: A quality assessment using cancer registry data. Fam Cancer 2007; 6: 131-34.
15. Wong C, Gibbs P, Johns J, et al. Value of database linkage: are patients at risk of familial colorectal cancer being referred for genetic counselling and testing? Intern Med J 2008; 38: 328-33.
16. Terdiman JP,. It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology 2005; 129: 741-4.
17. Sanchez JA, Vogel JD, Kalady MF, et al. Identifying Lynch syndrome: We are all responsible. Dis Colon Rectum 2008; 51: 1750-6.
18. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group: Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009; 11: 35-41.
19. Hampel H, de la Chapelle A,. The search for unaffected individuals with Lynch syndrome: Do the ends justify the means? Cancer Prev Res (Phila) 2011; 4: 1-5.
20. Kastrinos F, Syngal S,. Screening patients with colorectal cancer for Lynch syndrome: What are we waiting for? J Clin Oncol 2012: 30: 1024-7.
21. Western Australian Cancer Registry. http://www.health.wa.gov.au/wacr/ statistics/. Accessed on June 2013.
22. Schofield L, Grieu F, Carrello A, et al. Routine screening for Lynch syndrome in the Western Australian population using initial tumour MSI testing. Fam Cancer 2012; 11: 1-6.
23. Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006; 5: 2.
24. Chai SM, Zeps N, Shearwood AM, et al. Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin Gastroenterol Hepatol 2004; 2: 1017-25.
25. Hitchins MP, Rapkins RW, Kwok CT, et al. Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5UTR. Cancer Cell 2011; 20: 200-13.
26. Plazzer JP, Sijmons RH, Woods MO, et al. The InSiGHT database: Utilizing 100 years of insights into Lynch Syndrome. Fam Cancer 2013; 12: 175-80.
27. Heald B, Plesec T, Liu X, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol 2013; 31: 1336-40.
28. Watson N, Grieu F, Morris M, et al. Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn 2007; 9: 472-8.
29. Adackapara CA, Sholl LM, Barletta JA, et al. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 2013; 63: 187-93.
30. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. Ann Intern Med 2011; 155: 69-79.
31. Mvundura M, Grosse SD, Hampel H, et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12: 93-104.